Skip to main content
Erschienen in: Japanese Journal of Ophthalmology 1/2019

23.11.2018 | Clinical Investigation

Correlation between macular structure and function in patients with age-related macular degeneration treated with intravitreal ranibizumab: 12-month-results

verfasst von: Tomoharu Nishimura, Shigeki Machida

Erschienen in: Japanese Journal of Ophthalmology | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To determine the significance of the correlation between optical coherence tomographic (OCT) findings and focal macular electroretinograms (fmERG) at 12 months after beginning intravitreal injections of ranibizumab (IVR) in eyes with age-related macular degeneration (AMD).

Study design

Prospective, clinical study.

Method

We studied 28 eyes of 28 patients with AMD treated with IVR at monthly intervals for the initial three months. Additional IVR was given according to a pro re nata (PRN) regimen. OCT and fmERGs were performed preoperatively and at 3 and 12 months postoperatively. The fmERGs were elicited by a 15° white stimulus spot centered on the fovea. The thickness of the inner, middle, and outer layers of the retina and also of the serous retinal detachment (SRD) and pigment epithelial detachment (PED) in the horizontal and vertical meridians at 1.2 mm from the fovea (parafoveal) were measured in the OCT images.

Results

The b-wave amplitude at 12 months was significantly correlated with the thicknesses of the outer retinal layer, SRD, and PED (P=0.001–0.02). Multiple regression analyses showed that the outer retinal layer thickness was an independent determinant (P= 0.0001). The changes in the b-wave amplitude between the baseline and 12 months were significantly correlated with the changes in the SRD thickness (P=0.006). The changes in the b-wave amplitude during the PRN period were significantly correlated with the changes in the PED thickness (P=0.02).

Conclusions

At 12 months after beginning treatment, the reduction in the SRD thickness affects macular function recovery. As recurrences of the PED can occur during the PRN period, control of the PED is necessary to obtain good macular function for the long term.
Literatur
1.
Zurück zum Zitat Oshima Y, Ishibashi T, Murata T, Tahara Y, Kiyohara Y, Kubota T. Prevalence of age related maculopathy in a representative Japanese population: the Hisayama study. Br J Ophthalmol. 2001;85:1153–7.CrossRefPubMedPubMedCentral Oshima Y, Ishibashi T, Murata T, Tahara Y, Kiyohara Y, Kubota T. Prevalence of age related maculopathy in a representative Japanese population: the Hisayama study. Br J Ophthalmol. 2001;85:1153–7.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Yasuda M, Kiyohara Y, Hata Y, Arakawa S, Yonemoto K, Doi Y, et al. Nine-year incidence and risk factors for age-related macular degeneration in a defined Japanese population the Hisayama study. Ophthalmology. 2009;116:2135-40.CrossRefPubMed Yasuda M, Kiyohara Y, Hata Y, Arakawa S, Yonemoto K, Doi Y, et al. Nine-year incidence and risk factors for age-related macular degeneration in a defined Japanese population the Hisayama study. Ophthalmology. 2009;116:2135-40.CrossRefPubMed
3.
Zurück zum Zitat Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, MARINA study group, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31.CrossRefPubMed Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, MARINA study group, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31.CrossRefPubMed
4.
Zurück zum Zitat Brown DM, Kaiser PK, Michels M, Michels M, Soubrane G, Heier JS, et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–44.CrossRefPubMed Brown DM, Kaiser PK, Michels M, Michels M, Soubrane G, Heier JS, et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–44.CrossRefPubMed
5.
Zurück zum Zitat Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Lanchulev T, ANCHOR study group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116:57–65.CrossRefPubMed Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Lanchulev T, ANCHOR study group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116:57–65.CrossRefPubMed
6.
Zurück zum Zitat Johnston RL, Lee AY, Buckle M, Antcliff R, Bailey C, McKibbin M, UK AMD EMR Users Group, et al. UK age-related macular degeneration electronic medical record system (AMD EMR) users group report IV: incidence of blindness and sight impairment in ranibizumab-treated patients. Ophthalmology. 2016;123:2386–92.CrossRefPubMed Johnston RL, Lee AY, Buckle M, Antcliff R, Bailey C, McKibbin M, UK AMD EMR Users Group, et al. UK age-related macular degeneration electronic medical record system (AMD EMR) users group report IV: incidence of blindness and sight impairment in ranibizumab-treated patients. Ophthalmology. 2016;123:2386–92.CrossRefPubMed
7.
Zurück zum Zitat Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. VIEW 1 and VIEW 2 study groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537–48.CrossRefPubMed Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. VIEW 1 and VIEW 2 study groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537–48.CrossRefPubMed
8.
Zurück zum Zitat Ogura Y, Terasaki H, Gomi F, Yuzawa M, Iida T, Honda M, et al. VIEW 2 investigators efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study. Br J Ophthalmol. 2015;99:92–7.CrossRefPubMed Ogura Y, Terasaki H, Gomi F, Yuzawa M, Iida T, Honda M, et al. VIEW 2 investigators efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study. Br J Ophthalmol. 2015;99:92–7.CrossRefPubMed
9.
Zurück zum Zitat Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388–98.CrossRef Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388–98.CrossRef
10.
Zurück zum Zitat Dugel PU, Jaffe GJ, Sallstig P, Warburton J, Weichselberger A, Wieland M, et al. Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial. Ophthalmology. 2017;124:1296–304.CrossRefPubMed Dugel PU, Jaffe GJ, Sallstig P, Warburton J, Weichselberger A, Wieland M, et al. Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial. Ophthalmology. 2017;124:1296–304.CrossRefPubMed
11.
Zurück zum Zitat Yuzawa M, Fujita K, Wittrup-Jensen KU, Norenberg C, Zeitz O, Adachi K, et al. Improvement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degeneration. Ophthalmology. 2015;122:571–8.CrossRefPubMed Yuzawa M, Fujita K, Wittrup-Jensen KU, Norenberg C, Zeitz O, Adachi K, et al. Improvement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degeneration. Ophthalmology. 2015;122:571–8.CrossRefPubMed
12.
Zurück zum Zitat Nishihara H, Kondo M, Ishikawa K, Sugita T, Pia CH, Nakamura Y, et al. Focal macular electroretinograms in eyes with wet-type age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008;49:3121–5.CrossRefPubMed Nishihara H, Kondo M, Ishikawa K, Sugita T, Pia CH, Nakamura Y, et al. Focal macular electroretinograms in eyes with wet-type age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008;49:3121–5.CrossRefPubMed
13.
Zurück zum Zitat Iwata E, Ueno S, Ishikawa K, Ito Y, Uetani R, PIao CH, et al. Focal macular electroretinograms after intravitreal injections of bevacizumab for age-related macular degeneration. Invest Ophthamol Vis Sci. 2012;53:4185–90.CrossRef Iwata E, Ueno S, Ishikawa K, Ito Y, Uetani R, PIao CH, et al. Focal macular electroretinograms after intravitreal injections of bevacizumab for age-related macular degeneration. Invest Ophthamol Vis Sci. 2012;53:4185–90.CrossRef
14.
Zurück zum Zitat Nishimura T, Machida S, Harada T, Kurosaka D. Retinal ganglion cell function after repeated intravitreal injections of ranibizumab in patients with age-related macular degeneration. Clin Ophthalmol. 2012;6:1073–82.PubMedPubMedCentral Nishimura T, Machida S, Harada T, Kurosaka D. Retinal ganglion cell function after repeated intravitreal injections of ranibizumab in patients with age-related macular degeneration. Clin Ophthalmol. 2012;6:1073–82.PubMedPubMedCentral
15.
Zurück zum Zitat Ogino K, Tsujikawa A, Yamashiro K, Ooto S, Oishi A, Nakata I, et al. Intravitreal injection of ranibizumab for recovery of macular function in eyes with subfoveal polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci. 2013;54:3771–9.CrossRefPubMed Ogino K, Tsujikawa A, Yamashiro K, Ooto S, Oishi A, Nakata I, et al. Intravitreal injection of ranibizumab for recovery of macular function in eyes with subfoveal polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci. 2013;54:3771–9.CrossRefPubMed
16.
Zurück zum Zitat Takayama K, Kaneko H, Ueno S, Maruko R, Piao CH, Yasuda S, et al. Evaluation of short-term outcomes of intravitreal aflibercept injections for age-related macular degeneration using focal macular electroretinography. Retina. 2017;37:553–60.CrossRefPubMed Takayama K, Kaneko H, Ueno S, Maruko R, Piao CH, Yasuda S, et al. Evaluation of short-term outcomes of intravitreal aflibercept injections for age-related macular degeneration using focal macular electroretinography. Retina. 2017;37:553–60.CrossRefPubMed
17.
Zurück zum Zitat Miyake Y, Yanagida K, Kondo K, Ota I. Subjective scotometry and recording of local electroretinogram and visual evoked response. System with television monitor of the fundus. Jpn J Ophthalmol. 1981;25:439–48. Miyake Y, Yanagida K, Kondo K, Ota I. Subjective scotometry and recording of local electroretinogram and visual evoked response. System with television monitor of the fundus. Jpn J Ophthalmol. 1981;25:439–48.
18.
Zurück zum Zitat Miyake Y. Studies of local macular ERG. Acta Soc Ophthalmol Jpn. 1988;92:1419–49. Miyake Y. Studies of local macular ERG. Acta Soc Ophthalmol Jpn. 1988;92:1419–49.
19.
Zurück zum Zitat Nishimura T, Machida S, Hashizume K, Kurosaka D. Structures affecting recovery of macular function in patients with age-related macular degeneration after intravitreal ranibizumab. Graefe´s Arch Clin Exp Ophthalmol. 2015;253:1201–9.CrossRef Nishimura T, Machida S, Hashizume K, Kurosaka D. Structures affecting recovery of macular function in patients with age-related macular degeneration after intravitreal ranibizumab. Graefe´s Arch Clin Exp Ophthalmol. 2015;253:1201–9.CrossRef
20.
Zurück zum Zitat Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol. 2009;148:43–58.CrossRefPubMed Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol. 2009;148:43–58.CrossRefPubMed
21.
Zurück zum Zitat Hibi N, Ueno S, Ito Y, Piao CH, Kondo M, Terasaki H. Relationship between retinal layer thickness and focal macular electroretinogram components after epiretinal membrane surgery. Invest Ophthalmol Vis Sci. 2013;54:7207–14.CrossRefPubMed Hibi N, Ueno S, Ito Y, Piao CH, Kondo M, Terasaki H. Relationship between retinal layer thickness and focal macular electroretinogram components after epiretinal membrane surgery. Invest Ophthalmol Vis Sci. 2013;54:7207–14.CrossRefPubMed
22.
Zurück zum Zitat Machida S, Toba Y, Ohtaki A, Gotoh Y, Kaneko M, Kurosaka D. Photopic negative response of focal electroretinogram in glaucomatous eyes. Invest Ophthalmol Vis Sci. 2008;49:5636–44.CrossRefPubMed Machida S, Toba Y, Ohtaki A, Gotoh Y, Kaneko M, Kurosaka D. Photopic negative response of focal electroretinogram in glaucomatous eyes. Invest Ophthalmol Vis Sci. 2008;49:5636–44.CrossRefPubMed
23.
Zurück zum Zitat Tamada K, Machida S, Oikawa T, Miyamoto H, Nishimura T, Kurosaka D. Correlation between photopic negative response of focal electroretinograms and local loss of retinal neurons in glaucoma. Curr Eye Res. 2010;35:155–64.CrossRefPubMed Tamada K, Machida S, Oikawa T, Miyamoto H, Nishimura T, Kurosaka D. Correlation between photopic negative response of focal electroretinograms and local loss of retinal neurons in glaucoma. Curr Eye Res. 2010;35:155–64.CrossRefPubMed
24.
Zurück zum Zitat Kizawa J, Machida S, Kobayashi T, Gotoh Y, Kurosaka D. Changes of oscillatory potentials and photopic negative response in patients with early diabetic retinopathy. Jpn J Ophthalmol. 2006;50:367–73.CrossRefPubMed Kizawa J, Machida S, Kobayashi T, Gotoh Y, Kurosaka D. Changes of oscillatory potentials and photopic negative response in patients with early diabetic retinopathy. Jpn J Ophthalmol. 2006;50:367–73.CrossRefPubMed
25.
Zurück zum Zitat Sharma S, Toth CA, Daniel E, Grunwald JE, Maguire MG, Ying GS, Comparison of Age-related Macular Degeneration Treatments Trials Research Group, et al. Macular morphology and visual acuity in the second year of the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123:865–75.CrossRefPubMedPubMedCentral Sharma S, Toth CA, Daniel E, Grunwald JE, Maguire MG, Ying GS, Comparison of Age-related Macular Degeneration Treatments Trials Research Group, et al. Macular morphology and visual acuity in the second year of the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123:865–75.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Simader C, Ritter M, Bolz M, Deák GG, Mayr-Sponer U, Golbaz I, et al. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. Ophthalmology. 2014;121:1237–45.CrossRefPubMed Simader C, Ritter M, Bolz M, Deák GG, Mayr-Sponer U, Golbaz I, et al. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. Ophthalmology. 2014;121:1237–45.CrossRefPubMed
27.
Zurück zum Zitat Grunwald JE, Daniel E, Huang J, Ying GS, Maguire MG, Toth CA CA, CATT Research Group, et al. Research Group. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014;121:150–61.CrossRefPubMed Grunwald JE, Daniel E, Huang J, Ying GS, Maguire MG, Toth CA CA, CATT Research Group, et al. Research Group. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014;121:150–61.CrossRefPubMed
28.
Zurück zum Zitat Daniel E, Toth CA, Grunwald JE, Jaffe GJ, Martin DF, Fine SL, Comparison of Age-related Macular Degeneration Treatments Trials Research Group, et al. Risk of scar in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014;121:656–66.CrossRefPubMed Daniel E, Toth CA, Grunwald JE, Jaffe GJ, Martin DF, Fine SL, Comparison of Age-related Macular Degeneration Treatments Trials Research Group, et al. Risk of scar in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014;121:656–66.CrossRefPubMed
29.
Zurück zum Zitat Schmidt-Erfurth U, Waldstein SM, Deak GG, Kundi M, Simader C. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration. Ophthalmology. 2015;122:822–32.CrossRefPubMed Schmidt-Erfurth U, Waldstein SM, Deak GG, Kundi M, Simader C. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration. Ophthalmology. 2015;122:822–32.CrossRefPubMed
30.
Zurück zum Zitat Wolf A, Kampik A. Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research. Graefes Arch Clin Exp Ophthalmol. 2014;252:647–55.CrossRefPubMedPubMedCentral Wolf A, Kampik A. Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research. Graefes Arch Clin Exp Ophthalmol. 2014;252:647–55.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Giansanti F, Bacherini D, Giacomelli G, Virgili G, Finocchio L, Fiore T, et al. Intravitreal anti-VEGF therapy for vascularized pigment epithelium detachment in age-related macular degeneration. Eur J Ophthalmol. 2014;24:402–8.CrossRefPubMed Giansanti F, Bacherini D, Giacomelli G, Virgili G, Finocchio L, Fiore T, et al. Intravitreal anti-VEGF therapy for vascularized pigment epithelium detachment in age-related macular degeneration. Eur J Ophthalmol. 2014;24:402–8.CrossRefPubMed
32.
Zurück zum Zitat Essex RW, Nguyen V, Walton R, Arnold JJ, McAllister IL, Guymer RH, Fight Retinal Blindness Study Group, et al. Treatment patterns and visual outcomes during the maintenance phase of treat-and-extend therapy for age-related macular degeneration. Ophthalmology. 2016;123:2393–400.CrossRefPubMed Essex RW, Nguyen V, Walton R, Arnold JJ, McAllister IL, Guymer RH, Fight Retinal Blindness Study Group, et al. Treatment patterns and visual outcomes during the maintenance phase of treat-and-extend therapy for age-related macular degeneration. Ophthalmology. 2016;123:2393–400.CrossRefPubMed
33.
Zurück zum Zitat Balaskas K, Karampelas M, Horani M, Hotu O, Keane P, Aslam T. Quantitative analysis of pigment epithelial detachment response to different anti-vascular endothelial growth factor agents in wet age-related macular degeneration. Retina. 2017;37:1297–304.CrossRefPubMed Balaskas K, Karampelas M, Horani M, Hotu O, Keane P, Aslam T. Quantitative analysis of pigment epithelial detachment response to different anti-vascular endothelial growth factor agents in wet age-related macular degeneration. Retina. 2017;37:1297–304.CrossRefPubMed
34.
Zurück zum Zitat Cho HJ, Kim KM, Kim HS, Lee DW, Kim CG, Kim JW. Response of pigment epithelial detachment to anti-vascular endothelial growth factor treatment in age-related macular degeneration. Am J Ophthalmol. 2016;166:112–9.CrossRefPubMed Cho HJ, Kim KM, Kim HS, Lee DW, Kim CG, Kim JW. Response of pigment epithelial detachment to anti-vascular endothelial growth factor treatment in age-related macular degeneration. Am J Ophthalmol. 2016;166:112–9.CrossRefPubMed
35.
Zurück zum Zitat Yun C, Oh J, Ahn J, Hwang SY, Lee B, Kim SW, et al. Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2016;254:1693–702.CrossRefPubMed Yun C, Oh J, Ahn J, Hwang SY, Lee B, Kim SW, et al. Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2016;254:1693–702.CrossRefPubMed
36.
Zurück zum Zitat Zinkernagel MS, Wolf S, Ebneter A. Fluctuations in pigment epithelial detachment and retinal fluid using a bimonthly treatment regimen with aflibercept for neovascular age-related macular degeneration. Ophthalmologica. 2016;235:42–8.CrossRefPubMed Zinkernagel MS, Wolf S, Ebneter A. Fluctuations in pigment epithelial detachment and retinal fluid using a bimonthly treatment regimen with aflibercept for neovascular age-related macular degeneration. Ophthalmologica. 2016;235:42–8.CrossRefPubMed
Metadaten
Titel
Correlation between macular structure and function in patients with age-related macular degeneration treated with intravitreal ranibizumab: 12-month-results
verfasst von
Tomoharu Nishimura
Shigeki Machida
Publikationsdatum
23.11.2018
Verlag
Springer Japan
Erschienen in
Japanese Journal of Ophthalmology / Ausgabe 1/2019
Print ISSN: 0021-5155
Elektronische ISSN: 1613-2246
DOI
https://doi.org/10.1007/s10384-018-0642-1

Weitere Artikel der Ausgabe 1/2019

Japanese Journal of Ophthalmology 1/2019 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.